Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cerulean Pharma, a biopharmaceutical company, has appointed Oliver Fetzer as its new president and CEO. Dr Fetzer has also been elected to the company's board of directors.
Subscribe to our email newsletter
Dr Fetzer will succeed Alan Crane, who has been named chairman of the board of directors. In addition to serving as chairman of Cerulean, Mr Crane will assume the role of general partner at Polaris Venture Partners, where he has been a venture partner since 2002.
Most recently, Dr Fetzer was senior vice president of corporate development and R&D at Cubist Pharmaceuticals. Prior to joining Cubist, Dr Fetzer served as a managing director and partner at the Boston Consulting Group in the firm’s healthcare practice.
Mr Crane said: “We are extremely pleased that Oliver Fetzer will be assuming the role of CEO at Cerulean. As we move our first products towards the clinic and further demonstrate the power of our nanopharmaceutical platform, Oliver’s leadership, strategic and operational skills across science and business will be invaluable.”